Arpida Announces Review Of Iclaprim NDA By FDA Advisory Committee In November 2008
Arpida Ltd. (SWX: ARPN) announced that it has received notice from the U.S. Food and Drug Administration (FDA) that the agency’s Anti-Infective Drugs Advisory Committee will discuss the New Drug Application (NDA) for intravenous iclaprim in complicated Skin and Skin Structure Infections (cSSSI) during its meeting on 18-20 November 2008.
Mail this post 
Health is the Most Precious Asset to us! Just willing to share with you what I have learned from Nutriotional Immunology.
